Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959986 | 0.80 | IDE (0.31) | ABCB1 | |
| SCHEMBL14453034 | 0.80 | — | — | |
| SCHEMBL6936524 | 0.77 | GBA1 (0.31) | — | |
| SCHEMBL6155838 | 0.77 | GBA1 (0.31) | — | |
| SCHEMBL6155840 | 0.77 | GBA1 (0.31) | — | |
| SCHEMBL6158792 | 0.77 | GBA1 (0.31) | — | |
| SCHEMBL15275661 | 0.76 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL10000809 | 0.76 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL12500882 | 0.76 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL12849069 | 0.76 | NPC1 (0.32) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070530-B1 | Treatment of diseases associated with the use of antibiotics | MERCK SHARP & DOHME (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20130274175-A1 | TREATMENT OF DISEASE ASSOCIATED WITH THE USE OF ANTIBIOTICS | OPTIMER PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274175-A1 | TREATMENT OF DISEASE ASSOCIATED WITH THE USE OF ANTIBIOTICS | OPTIMER PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20070173462-A1 | Treatment of diseases associated with the use of antibiotics | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173462-A1 | Treatment of diseases associated with the use of antibiotics | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274175-A1 | TREATMENT OF DISEASE ASSOCIATED WITH THE USE OF ANTIBIOTICS | POLI, APC, VIL1 | MAPT 2104/4885ABCB1 58/4885MAPK1 984/4885 |
| US-20070173462-A1 | Treatment of diseases associated with the use of antibiotics | POLI, APC, VIL1 | MAPT 1963/4885ABCB1 41/4885MAPK1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.